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Abstract: This review evaluates methods, success and limitations of transgenes delivery in central 
nervous system (CNS). Both viral and nonviral (such as liposome mediated) methods, expression 
and stability of transgenes have been discussed. The controlled expression and delivery techniques 
of transgene at the injured or diseased sites have also been discussed. Mifepristone (RU486) and 
tetracycline-based switch system for controlled expression could be a very useful tool for clinical 
purposes. Here we emphasized the importance and consequences of viral- and nonviral-mediated 
transgenes transfer and therapeutic ability along with advantages of controlled expressions.
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Introduction
Damaged neuronal cells in the central nervous system (CNS) could not be repaired/
regenerated, leading to a partial disability or complete paralysis due to disruption of 
communication between brain and body. However, new ﬁ  ndings and developments in 
the gene therapy techniques related to CNS have improved the prospects for recovery 
to some extent. While research in this ﬁ  eld is still in the early stage, this work could 
lead to the clinical applications that can help to restore lost functions in the wake of 
brain and spinal cord injury. Development of new viral and nonviral vectors with cell 
type speciﬁ  c, physiologically-relevant and long term transgene expression at speciﬁ  c 
site is under progress. Nonviral vector such as cationic1,2 and anionic liposome3 shows 
no-immune response or toxicity to host. Genetically engineered cells and direct DNA 
transfer4 have also shown potential in certain experimental paradigms. This review 
provides an update and recent advancement in the gene therapy techniques related to 
CNS diseases and injuries.
Potentials of therapeutic genes in CNS injury and disorders
Many therapeutics genes, such as nerve growth factor (NGF), brain-derived neuro-
trophic factor (BDNF), B-cell lymphoma-2 (BCL-2), heat shock protein (HSP), etc, 
could be used to prevent and cure CNS related injuries or disorders (Table 1).
NGF gene for therapeutic applications
Nerve growth factor (NGF) is the prototypical neurotrophic factor having ability to protect 
peripheral sensory and sympathetic neurons from programmed cell death (apoptosis).5 
Studies done so far have shown that direct CNS administration of recombinant growth 
factors including NGF can rescue damaged neurons and promote regeneration.2,6 In 
addition, NGF is able to protect adult sensory and sympathetic neurons against a variety 
of insults that include axotomy, ionophore treatment, exposure to hydrogen peroxide 
and excitatory amino acids.7,8 Localized diffusion of gene products into targeted region 
of CNS parenchyma could secrete proteins only within CNS regions relevant to neuro-
pathological states, thus limiting the peripheral side effects.9 The intracerebroventricular Biologics: Targets & Therapy 2009:3 246
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injection of NGF gene increases mNGF (messenger RNA of 
NGF) levels in the hippocampus that causes increased choliner-
gic neurotransmitter synthetic enzyme choline acetyltransferase 
(ChAT) activity within the brain.9 Chronic intraventricular 
injection of rhNGF (recombinant human Nerve growth factor) 
via cannulae for 21 days increased synaptosomal high afﬁ  nity 
choline uptake, choline acetyltransferase activity, and [3H] 
acetylcholine synthesis by 50%–90% compared to lesion 
control values.10 Cholinergic neurotransmission deﬁ  cits after 
traumatic brain injury (TBI) might be the result of presynaptic 
alterations in the storage and release of acetylcholine (Ach) or 
due to conformational changes in the receptors for Ach.11
BDNF gene for therapeutic applications
Brain-derived neurotrophic factor (BDNF) is well docu-
mented for their therapeutic role in the development and 
survival of injured CNS. BDNF is known to stimulate axon 
outgrowth, branching, proliferation, differentiation, and can 
work as neurotransmitter.12 BDNF have also been implicated 
in synaptic plasticity,13 long-term memory,14 and expression 
of NMDA receptors.15 Loss of NMDA receptors is a cause 
of memory impairment16,17 after injury.18,19 BDNF is found 
in soluble form and induces differentiation and survival 
of neurons by binding to its receptor known as trkB. TrkB 
receptors are present in three isoforms, namely full length 
isoform TK+, and two truncated isoforms, TKT1 and TKT2, 
in the cellular membrane of mammalian CNS. In fact, trkB is 
a part of tyrosin kinase receptor group20 capable of adding a 
phosphate group at tyrosin/serine/theronine residues on target 
proteins after interaction with BDNF. While trkB kinase is 
activated by BDNF, NT-3, and NT-4, but the other subtypes 
trkA and trkC are activated by NGF and NT-3, respectively. 
The cationic lipid-mediated BDNF gene transfection in primary 
hippocampal cell cultures enhances recovery of neuroﬁ  lament 
loss produced by CNS injury.1 BDNF gene transfection could 
increases phosphoinositide 3-kinases (PI3-kinases) activity 
in CNS cells. PI-3 kinases are family of related enzymes 
capable of phosphorylating the 3-position hydroxyl group 
of the inositol ring of phosphatidylinositol. PI-3 kinases play 
important role in a variety of cellular responses such as mito-
genesis, membrane trafﬁ  cking and preventor of apoptosis.21 
Moreover, BDNF has been shown to induce anti-apoptotic 
mechanisms after stroke that reduces infarct size and secondary 
neuronal cell death. BDNF is also a potent stimulator of adult 
neurogenesis.22 Apart from that BDNF is able to protect the 
brain from inﬂ  ammatory brain injury in bacterial meningitis.23 
Increasing the level of BDNF is an effective way to decrease 
mortality and to improve sequela upon bacterial meningitis.
BCL-2 gene for therapeutic applications
BCL-2 gene is known for the synthesis of anti-apoptotic protein. 
The name BCL-2 has been derived from B-cell lymphoma 2, 
and its anti-apoptotic group includes BCL-2 proper, BCL-xl, 
and BCL-w. Herpes simplex virus (HSV)-mediated delivery of 
BCL-2 gene into hippocampus and striatum in vivo can attenuate 
the damaging effects of ischemic brain.24 Over-expression of 
BCL-2 gene prevents the release of apoptosis-inducing factor.25 
The post-ischemic injection of adeno-associated virus (AAV)-
containing BCL-2 gene has a neuroprotective effect that inhibits 
ischemic neuronal cell death.26 BCL-2 gene may also delay 
disease progression in chronic degenerative disorder such as 
Parkinson’s disease.27 6-Hydroxydopamine (6-OHDA) is a 
Table 1 Therapeutic applications of various genes in central nervous system diseases and their current status
S No. Gene types Diseases Current status References
1. NGF Alzheimer’s disease (AD), Huntington’s 
disease, Neuroblastoma, Neuronal tube 
defects (NTD), Seizure
Phase I clinical trial is in progress
Over-expression of NGF is able to 
sort out the problems related with NTD
110–115
2. BDNF Bacterial meningitis (BM), Parkinson 
disease (PD), Fragile X syndrome
BDNF rescues from BM and genetic 
variation in BDNF affect risk for PD
23, 116
3. BCL-2 Parkinson disease, Ischemic brain injury BCL-2 inhibits caspase-3 activation 
and DNA fragmentation.
24, 27, 117
4. HSP70/72/75 Focal cerebral ischemia HSP protect and improves the 
neuron survival
32, 118
5. IL-lra Ischemia and local brain injury, Seizure, 
Neurotrauma
Different family of IL-1ra reduces 
the risk of different kinds of CNS injuries
119, 119
6. Combination of 
NGF/BDNF/BCL-2/HSP 
genes
Various other neurological diseases Combination of genes could short 
out many neurological/CNS diseases
Work is in 
progress
Abbreviations: BCL-2, B-cell lymphoma-2; BDNF, brain-derived neurotrophic factor; HSP, heat shock protein; IL-lra, interleukin-lra; NGF, nerve growth factor.Biologics: Targets & Therapy 2009:3 247
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neurotoxin to dopaminergic neurons. BCL-2 produced by the 
vector prevented 6-OHDA-induced degeneration of neurons 
and increased the surviving capabilities of TH (tyrosine 
hydroxylase) immunoreactive neurons in the Substantia 
Niagra two weeks after the lesioning.28 Administration and 
expression of BCL-2 gene in adult rat CNS neurons prevent 
retrograde cell death and minimizes atrophy.29 In vivo neuro-
protection of injured CNS neurons occurs by an injection of a 
DNA plasmid encoding the BCL-2 gene.30 Overexpression of 
BCL-2 gene in primary cultured neurons protects an insult in 
cAMP receptor dependent manner, whereas protection is not 
seen against severe traumatic insults.31 These informations 
will provide a new insight into the molecular therapeutics for 
neurodegenerative conditions in future.
HSP72 genes for therapeutic applications
Heat shock protein 72 (HSP72) protein is expressed into 
the brain after stroke and seizures and is able to remove 
denatured proteins from a cell to assist new protein synthesis. 
Gene transfer therapy with defective HSV-vector over 
expressing HSP72 improves neuronal survival against focal 
cerebral ischemia and systemic kainic acid administration.32 
Overexpression of HSP72 gene into rat brain can improve 
striatal and hippocampal dentate gyrus neuron survival after 
systemic kainic acid administration. The transgenic mice 
over-expresing HSP72 could attenuated hippocampal injury 
after focal cerebral ischemia.33
Interleukin-1 receptor antagonist genes 
for therapeutic applications
Interleukin-1 (IL-1) acts as a cofactor and is responsible 
for inﬂ  ammatory reaction after transient ischemia and local 
brain injury. Central and systemic administration of an IL-1 
receptor antagonist (IL-1ra) reduces ischemic brain injury in 
short-term. IL-1ra is usually produced by the normal brain cells 
that produce IL-1. The adenovirus vector mediated over expres-
sion of human IL-1ra gene can attenuate ischemic inﬂ  ammatory 
response in the mouse brain and inﬂ  ammation based neuronal 
diseases.34 The mechanism involves binding of IL-1ra to the 
receptor of IL-1 preventing inﬂ  ammatory reaction in ischemic 
cortex, striatum and corpus callosum regions. It is still unknown 
whether IL-1 is responsible for neuronal cell death directly or 
exacerbates other forms of damage or both.
Ex vivo transfer mediated 
therapeutic applications 
for CNS injury and disorders
Ex vivo gene transfer is a potential means of treating chronic 
neurological disorders and injury related neural degeneration. 
In this approach cells are modiﬁ  ed genetically in vitro and 
then transplanted to the injured site of CNS. Injured cell 
replacement therapy is not suitable due to the blood–brain 
barrier (BBB). To circumvent the BBB, ex vivo gene therapy 
is most acceptable and is able to traverse the BBB or other 
membranes of the CNS. Fibroblast, peripheral nerves, astro-
cytes, and myoblasts cells could be used for the ex vivo gene 
therapy in the CNS.
Fibroblast cells modiﬁ  ed with NGF genes have been 
transplanted into the brain and spinal cord to provide neu-
rotrophic factors and substrates for axonal growth and elon-
gation. NGF secreting ﬁ  broblast cells transplant have been 
shown to prevent degeneration of cholinergic neurons in the 
basal forebrain of primates. Transplant induces sprouting of 
sensory, motor, and noradrenergic neurites after spinal cord 
injury. The controlled and targeted expression of tetracycline-
regulated ex vivo delivery of NGF is possible at transplanted 
sites.34 Genetically transduced Schwann cells grafted to 
spinal cord injury sites increase axonal growth by the over 
expression of NGF.35,36 When ﬁ  broblasts cells, genetically 
modiﬁ  ed to secrete NGF, BDNF, NT-3, and basic ﬁ  broblast 
growth factor (bFGF), transplanted into the central gray mat-
ter of the spinal cord in the adult rats, sensory neurites of 
dorsal root origin extensively penetrated NGF-, NT-3-, and 
bFGF-secreting grafts, whereas no growth has been found 
in BDNF-secreting grafts.37
Injured CNS tissues and damaged neurons are unable to 
regenerate their axons spontaneously. Genetically modiﬁ  ed 
peripheral nerves can be implanted ex vivo, in transected 
sciatic nerve, avulsed ventral root, hemi-sected spinal cord, 
and intact brain to overexpress the transgene encoding growth 
promoting NT-3 proteins that improves the permissive proper-
ties of the nerves.15 The rat ﬁ  broblasts, genetically modiﬁ  ed to 
produce NT-3, grafted to acute spinal cord dorsal hemisection 
lesion cavities showed signiﬁ  cant partial functional recovery 
in corticospinal axon growth at distal to the injury site.38
Astrocytes originated from CNS have efﬁ  cient secretory 
mechanisms to play an important role in neuronal growth. 
Human adult astrocytes modiﬁ  ed with speciﬁ  c transgene 
could be used for ex vivo gene therapy. Ex vivo cell trans-
plantation decreases the chances of immunological rejection 
at minimum level and thus obviating the side effects of 
immunosuppressors.39
Myoblast cells40 and astrocytes41 could be genetically 
modiﬁ  ed to express tyrosine hydroxylase (TH) and dopa-
mine in culture. These modiﬁ  ed myoblasts, not showing 
immuno-rejection property, might be used as gene carriers 
for ex vivo gene therapy in the CNS. Thus, ex vivo gene Biologics: Targets & Therapy 2009:3 248
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therapy in the CNS could be an efﬁ  cient and convenient tool 
for the future.42 Deﬁ  ciency of beta-glucuronidase (GUSB) 
causes multisystem progressive degenerative syndrome, 
mucopolysaccharidosis (MPS) type VII (Sly disease), in 
adult brain that could be cured by transplanting engineered 
GUSB-secreting cells to super-secrete the normal enzyme 
for export to surrounding neural tissues.43
Controlled expression of therapeutic 
genes in CNS
There is a need to control the transgene expression to prevent 
adverse effects of overexpression. The concept of molecular 
switches is based on the use of tissue-speciﬁ  c promoters, 
which confers restricted expression of transgene appropri-
ately within the tissue. Appropriate regulation means the 
capability of the system to turn the transgene on and off in 
response to symptoms (expression) of the targeted disease. 
Many gene switch systems are available to control transgene 
expression but in CNS, mifepristone (RU486), and tetracy-
cline (tet)-based switch systems are important.
Transgene regulation by inducible 
promoter (mifepristone)
Transgene expression can be controlled by using a speciﬁ  c 
promoter whose activity can be controlled by mifepristone,44 
a progesterone hormone antagonist. Mifepristone is a 
19-nonsteroid which has a speciﬁ  c high afﬁ  nity binding to 
the progesterone and glucocorticoid receptor. Mifepristone-
responsive gene switch system has become most attractive 
for an application in traumatized CNS. The synthetic 
progesterone antagonist readily crosses the BBB when 
administered systemically.45 In this system the transgene 
to be regulated is placed under transcriptional control 
of a promoter, which in turn is activated by a speciﬁ  c 
transactivator, consisting of a fused tripartite protein. The 
tripartite proteins are Gal4 (Yeast DNA-binding domain), 
HBD (mutated progesterone receptor that binds speciﬁ  cally 
to mifepristone), and VB 16 (activation factor derived 
from HSV). The vector used for gene therapy encodes the 
fusion protein, and either a cytomegalovirus (CMV) or 
tissue-speciﬁ  c promoter, which drives its expression after 
delivery. In its native state, the transactivator does not 
induce transgene transcription but binding of mifepristone 
to the transactivator enable the administered transactivator 
to immediately initiate the transgene expression. This 
switch system has been used to regulate genes systemically 
when transferred with either plasmid DNA46 or adenoviral 
vectors,47 or in conjunction with HSV vector-mediated gene 
transfer.48 With inclusion of a mifepristone-responsive gene 
switch into gene delivery vector, transgene expression could 
be regulated according to therapeutic need.
Transgene regulation by tetracycline 
antibiotic-based gene switch
Tetracycline-based switch system is based on the use 
of inducible elements and factors along with transgene, 
regulated by the administration of a second-step drug or 
by the end product. Based on the above principle, highly 
controlled gene expression of recombinant Ad and AAV 
vectors using combinations of a tissue-speciﬁ  c promoter and 
a tetracycline transcription factor have been constructed.49 
Thus, it is possible to transfer a putative therapeutic gene to 
speciﬁ  c tissue in a completely dormant state. Expression of 
the dormant gene can be induced by the oral administration 
of a second-step drug (rapamycin or mifepristone) that directs 
the formation of an active transcription factor complex on 
the silent promoter of the transferred gene. Despite the above 
information, no literature is available to show a switch based 
promoter in AAV vector for the transfer of therapeutic gene 
in brain injury. In contrast, a switch based promoter with 
stable expression of a constitutive AAV-erythropoietin vector 
in non-CNS tissues has been successfully demonstrated. 
Moreover, the regulation of tet-promoter is simple because 
gene induction or repression is being controlled by only 
one protein. Also, this switch system can be packaged into 
a single vector due to smaller size of tet-transactivator and 
tet-regulatable promoter. The minimal CMV promoter is 
fused to the tet-operator sequence to stimulate transcription 
of tet-transactivator in the absence of tetracycline. Tet-
regulatable gene expression system can release NGF-GFP 
(green ﬂ  uorescent protein) in a controlled manner from 
primary rat ﬁ  broblasts in a dose-dependent manner by the 
exposure to the tet analog doxycyline.50
Recent developments in CNS 
gene delivery vectors/carriers
Many techniques (such as viral and nonviral vectors, 
chemical carriers, and physical forces) could be used for 
targeted delivery of transgenes at the diseased or injured 
CNS site (Figure 1).
Viral vectors for CNS therapeutic 
gene delivery
Viral vectors have become important tool for the gene 
delivery at particular site in the brain. Different strategies are Biologics: Targets & Therapy 2009:3 249
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used to deliver genes to CNS and enhance its distribution. 
One way is to inject the viral vectors directly into the cerebral 
lateral ventricles (LVs). By this way, virus will be delivered 
throughout the CNS.51 Another way is to inject at multiple 
sites to cover a large volume. Some agents such as Mannitol52 
and heparin53 are used to increase the distribution of vectors. 
Some important viral vectors have been discussed below.
Simple viral vectors
Herpes simplex virus (HSV) vectors
HSV is a neurotrophic virus having ability to establish a 
life-long latent state in neurons. It is an enveloped (envelope 
contains at least 10 glycoproteins) double-stranded DNA 
encoding more than 80 identiﬁ  ed genes bearing 152 kb 
viral genome. HSVs infect neurons by rapid retrograde 
axonal transport mechanism, thus providing a means of 
gene transfer to targeted cells that are not easy to reach 
directly.54 Two types of HSV-vectors were constructed for 
gene transfer: recombinant virus (RV) and amplicon vectors. 
Recombinant replication-conditional viruses contain one 
or more mutated genes (such as r34.5 or ICP6) in the full 
genome to reduce overall toxic effects. Replication defective 
RV vectors or multiplication-defective genomic HSV vec-
tors were constructed by deleting all immediate-early (IE) 
genes such as ICP0,55 ICP4, ICP22, ICP27, and ICP4756,57 
that encode transactivating factors. Such deletion eliminated 
expression of other viral genes56,58 that may be toxic to cells. 
These multiple gene-deleted vectors have many advantages: 
(a) can propagate to high titers in the complementing cell 
lines, and (b) long-term expression of latency associated 
transcripts (LATs) in genome does not depend on IE-genes. 
This provided a chance to construct a highly defective HSV-
vector that can readily persist in a latent state in neurons, and 
transgenes could be expressed using the LAT promoter. Basi-
cally HSV amplicon based vectors are plasmid-based DNA 
constructs. A typical HSV amplicon construct contains, in 
addition to the gene of interest, a copy of HSV replication 
origin (oris) and packaging signal (pac). When these vectors 
were introduced into cells together with a helper HSV, the 
amplicon plasmid DNA efﬁ  ciently ampliﬁ  ed and packaged 
into viral particles. Helper virus free amplicon stock could 
be generated by co-transfecting amplicon set of cosmids 
or BAC plasmids containing fragmented or modiﬁ  ed HSV 
genome.59
The HSV amplicon mediated gene transfer has many 
advantages over recombinant HSV vectors. These advantages 
include nontoxic and nonimmunogenic responses to the target 
cells, since amplicon based vectors do not encode any viral 
gene products. Amplicon is a multiple gene delivery system 
because each amplicon contains 10–15 copies of the inserted 
gene due to its concatemeric form. This gives much higher 
expression of transgene in comparison to recombinant virus 
• HSV
• Lentivirus
• Retrovirus
• Recombinant adeno-associated virus
  (rAAV)   
• SV40 virus
• Helper-dependent adenoviral vector
  (hdAdV)
• HSV/AAV hybrid
• HSV/EBV
• HSV/EBV/Retrovirus
• Ad/AAV
• Ad/Retrovirus
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• FuGene6
• Poly[α-(4-aminobutyl)-L-glycolic
  acid] (PAGA) 
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Figure 1 Vehicles for gene delivery in central nervous system to regenerate the damaged cells.
Abbreviations: AAV, adeno-associated virus;   Ad, adenovirus; EBV, Epstein–Barr virus; HSV, herpes simplex virus; SV-40, simian virus 40.Biologics: Targets & Therapy 2009:3 250
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containing similar type of gene cassette.60 Moreover, it is 
easy to insert gene of choice into amplicon vectors that has 
long-term transgene expression in different areas of CNS.61 
In order to improve the proportion of amplicons generated, 
a selection system for amplicon production is developed in 
which the HSV thymidine kinase (TK) gene is inserted into 
an amplicon plasmid and an HSV mutant with both TK and 
glycoprotein H (gH) genes deleted is used as a helper.60 HSV 
virus has been designed in which the prokaryotic Cre–loxP 
site-speciﬁ  c recombination system is employed. In this 
system, gH-helper virus is engineered in such a way that 
loxP sites ﬂ  ank both copies of its packaging signals and thus 
generated stocks with high amplicon titer and much improved 
amplicon over helper virus ratio. The injection and expression 
of HSV vectors containing β-NGF gene under the transcrip-
tional control of either human cytomegalovirus immediate 
early promoter (HCMV Iep) element or HSP-latency active 
promoter (HSV-LAP2) produced biologically active NGF in 
transfected PC-12 cells. HSV virus-mediated NGF synthesis 
induces expression of superoxide dismutase and catalase, 
and is effective in protecting cells from apoptosis induced 
by hydrogen peroxide.62 Replication defective genomic 
HSV vector mediated transfer of β-NGF, under the control 
of either the LAP2 or HCMV Iep promoter, into the knee 
joint of animals has been effective for treatment of peripheral 
neuropathesis.57 Amplicon HSV has a lot of advantages but 
it still has some limitations because it is usually difﬁ  cult to 
generate a stock with a high amplicon titer and high ratio of 
amplicon to helper virus.
Lentivirus vectors
Lentivirus vectors are derived either from the HIV-1 
(human immunodeficiency virus type-1) vector or FIV 
(feline immunodeficiency virus) vector after genetic 
manipulation63,64 and able to carry 8 kb of sequence to any 
neuronal cell type with sustained expression in which normal 
cellular functions are not compromised either in vitro or in 
vivo.65 HIV-1-derived vectors have ability to integrate into 
the host genome of dividing and nondividing cells, and 
hence can be utilized for the transfer of genes with stable 
expression even in post-mitotic neurons. Lentiviral vector-
encoded beta-galactosidase transgene showed very efﬁ  cient 
transfer, integration, and sustained long-term expression 
without showing any pathology in adult rat brains. In vivo 
gene transfer using lentiviral vector depends on a functional 
integrase protein.66 A recent report suggests that lentiviral 
vectors surpass retroviral vectors in efﬁ  cient long-term 
and stable gene transfer in adult neural stem cells.67 On the 
other hand, the HIV-1 has a broad host range and can infect 
brain, liver, and muscle cells. The targeted transduction of 
transgene in the CNS was achieved using speciﬁ  c envelope 
glycoproteins to pseudotype lentivrial vectors. The use of 
Ebola-pseudotyped virus, Mokola-pseudotyped, and murine 
leukemia virus (MuLV)-pseudotyped lentiviral vectors are 
more efﬁ  cient and stable alternatives to vesicular stomatitis 
virus glycoprotein (VSV-G)-pseudotyped vector gene for 
the transduction of transgene in mouse CNS.68 Despite of 
these developments the clinical application of both the 
HIV-1 and FIV vectors for CNS has yet to be conﬁ  rmed 
experimentally.
Retrovirus vectors
The higher and unequal efﬁ  ciency of retroviral vectors to 
integrate their genome into host cell chromosomal DNA 
has made it the ﬁ  rst choice for many gene therapy applica-
tions. In many clinical trials so far no single case has been 
reported which attributes adverse events of insertional 
mutagenesis, caused by retrovirus vector application. The 
vectors have 8.5 kb of transgenes ﬂ  anked by retroviral long 
terminal repeat (LTR) regions, a virion packaging signal, and 
a primer binding site for reverse transcription. After delivery 
into cells, double-stranded DNA sequences can be reversely 
transcribed which can then get integrated randomly into host 
cell genome. This vector has limited use for gene delivery to 
CNS because of their ability to transfer genes only to dividing 
cells, yet have been well suited for on-site delivery to neural 
precursors for lineage studies.69
Recombinant adeno-associated viral (rAAV) vectors
There are 11 AAV serotypes have been reported so far.70–72 
They infect cells from several diverse tissue types. Capsid 
serotype is the main determinant of tissue speciﬁ  city and 
pseudotyping of AAV vectors to alter their tropism range 
for their use in gene therapy. Different serotypes can bind 
to different cellular receptors. Among these, serotype 2, 4, 5 
(AAV2, 4, 5) have been studied most extensively73,74 and are 
found efﬁ  cient for transduction in the mammalian brain.73 
rAAV vector is the vector of choice for gene delivery to 
neurons due to several advantages: (a) easy to manipulate 
genetically, (b) ability to transduce most tissues including 
terminally differentiated cells, (c) puriﬁ  cation to high titers, 
and are (d) relatively safe. The replication defective recom-
binant adenoviruses are commonly used as gene transfer 
vectors because of their less immunogenicity and ability to 
transduce both neurons and glial cells efﬁ  ciently.75 rAAV-
mediated in vivo gene transfer has demonstrated efﬁ  cient Biologics: Targets & Therapy 2009:3 251
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long-term transduction (from three months to more than 
1.5 years), lack of cytotoxicity and cellular immune response 
in target tissues, especially in the CNS.76
The contamination risk could be eliminated in rAAV 
production by (i) substituting adenovirus with a plasmid-
bearing E2a, E4orf6, and VA helper function, and (ii) growing 
on HEK 293 cells which express Ad E1a and E1b.77,78 There 
are two types of toxicity due to (a) aggregation of rAAV 
with cell lysate proteins, and (b) residual hyperosmotic CsCl2 
during puriﬁ  cation step.79 Both types of toxicity could be 
removed by substitution of density centrifugation with iso-
osmotic and inert medium iodixanol. Afﬁ  nity chromatography 
is being used for high level of puriﬁ  cation of rAAV.80,81 
The heparin sulfate proteoglycan (a cellular receptor for 
attachment and infectivity of AAV-281) and virion-speciﬁ  c 
monoclonal antibodies82 could be utilized as core facility 
for the puriﬁ  cation and production of rAAV using ligand 
speciﬁ  c matrix chromatography. Moreover, rAAVs have 
been developed having capability to express human proto-
oncogene BCL-236 that confers an ability to block neuronal 
death after transient ischemia. rAAVs have capability to 
package 6.6 kb vector sequence that could be used for gene 
therapy for hemophilia A and other diseases with large cDNA 
such as muscular dystrophy and cystic ﬁ  brosis.83
Aromatic L-amino acid decarboxylase (AADC) 
converts L-dopa to dopamine. The AADC gene encoded in 
rAAV vectors has been used for therapy purposes to treat 
Parkinson’s disease.84 Prevention of dopaminergic neuron 
death by AAV vector-mediated glial cell derived neuro-
trophic factor (GDNF) gene transfer in rat mesencephalic 
cells has also been reported.85 The behavioral recovery in 
5-hydroxydopamine-lesioned rats by co-transduction of 
striatum with tyrosine hydroxylase and AADC genes using 
two separate AAV vectors is possible.85 Although, rAAV has 
shown its potential in gene therapy, further improvements 
are needed to consider for clinical uses.
Simian virus 40 (SV40) vectors
SV40 virus is a member of the nonenveloped particle of 
polyoma family of viruses with double stranded circular DNA 
genome of 5.25 kb. SV40-derived vectors can express both 
in vitro or in vivo with long term transgene expression either 
into caudate-putamen or lateral ventricle after injection.86 
For transgene expression in CNS, rAAV utility is measured 
in comparison to SV40. SV40 can package genomes up 
to 5.7 kb without difﬁ  culty after deleting structural genes. 
rSV40s (recombinant SV40) do not elicit detectable neutral-
izing antibody responses.87
Helper-dependent adenoviral vectors
Third generation adenovirus vectors (AdV), called gutless 
or helper dependent adenoviral vector (hdAdV), have 
been developed that retain only the sequences necessary 
for packaging and replication of viral genome and lack all 
structural genes75 thus extending the cloning capacity of the 
vector (up to 37 kb). This novel construct has capacity to 
propagate to high titers without contaminating helper Ad virus 
using a Cre-lox-based recombinase system. Gene transfer by 
hdAdV demonstrated persistent gene expression with negligi-
ble toxicity in peripheral organs such as liver.88,89 hdAdV has 
been used to transduce genes to CNS for stable gene transfer 
that signiﬁ  cantly prolonged transgene expression (up to 183 
days).89 The number of macrophages and T lymphocytes 
inﬁ  ltrating the brain could be greatly reduced in hdAdV-
treated host in comparison to ﬁ  rst generation adenovirus 
(fgAd)-treated host.6 The hdAdV provides equally eff icient 
or higher infectivity but signif icantly reduced toxicity than 
fgAd vectors.90 Low toxicity is extremely important for 
the clinical applications of hdAdV as a future tool for gene 
delivery to CNS. Studies delivering α−antitrypsin and leptin 
gene using hdAdVs in vitro or in vivo have shown that these 
fully deleted Ad vectors can provide high-level, long-term 
gene expression with improved tolerance due to absence 
of the viral genome.88,89 However, hdAdV infection causes 
moderate but signiﬁ  cant changes in cell function and viability 
at excessive viral titers in primary neuronal cultures.91
The expected improvements for clinical use of hdAdVs 
are: (1) to remove all helper viruses from the hdAdV 
preparation to avoid even trace amount of contamination, 
(2) development of targeted hdAdVs to localize gene trans-
fer to speciﬁ  c cell types, (3) production of high-titer vector 
without the cost of contamination by wild-type AAV, and 
(4) use of molecular switches for controlled expression of 
transgene by the vectors. Moreover, it is possible that some 
of improvements can be achieved through the construction 
of hybrid viral vectors utilizing two different viruses.
Hybrid viral vectors
These vectors are also known as chimeric or hybrid viral 
vectors and constructed or developed to achieve reproducible 
and stable gene delivery to the CNS or other parts of the 
body. Such kind of hybrid vectors has been constructed to 
incorporate different viral elements with particular features 
to stabilize the transgenes at transfected site. Various types of 
vectors have been constructed by utilizing the combination of 
two or more viral elements or gene sources. Some important 
hybrid viral vectors have been discussed below.Biologics: Targets & Therapy 2009:3 252
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HSV/AAV hybrid amplicon vectors
The hybrid amplicon vectors contain oris and pac signals of 
HSV-1 and ITR sequences of AAV to ﬂ  ank the transgene. 
It was produced either with or without the AAV rep gene 
to evaluate its importance in producing sustained transgene 
expression in human glioma cells.92 The hybrid amplicon 
vector extended transgene expression in dividing human 
glioma cells well beyond the capacity of HSV amplicons. 
Higher transduction efﬁ  ciency in primary neuronal cultures 
and longer expression of the transgene in neurons were 
also noted in hybrid amplicon-mediated gene transfer in 
comparison to AAV and AdV.93,94
HSV/EBV and HSV/EBV/retrovirus hybrid 
amplicon vectors
Amplicon elements of HSV, latent origin of DNA replication 
(ori-P), and Epstein–Barr nuclear antigen-1 gene (EBNA-1) 
elements of Epstein–Barr virus (EBV) are used to construct 
HSV/EBV hybrid vector. Inclusion of ori-P and EBNA-1 
increased the stability of transgene during replication in the 
dividing cells.95 A hybrid vector having the character of HSV 
and retrovirus has also been constructed.96,97 This hybrid 
HSV/retrovirus vector confers ability of retrovirus vector 
to transduce into both dividing and nondividing cells in a 
single step of infection. Since this new construct has ability to 
transduce into nondividing cells it can be efﬁ  ciently utilized 
for the transfer of gene in CNS.
Ad/AAV hybrid vectors
This hybrid vector encodes the AAV Rep78 protein and an 
ITR-ﬂ  anked transgene.98 Another type of Ad/AAV vector 
consist of an AAV ITR-ﬂ  anked transgene in which the AAV 
Rep isoforms are conjugated to the Ad-virion via poly-lysine 
bridge to site speciﬁ  c delivery of the transgene.
Ad/retrovirus hybrid vectors
This chimeric vector is constructed to increase the transfec-
tion capability and to successful expression of transgene in 
the neighboring cells. When any cell is transfected by the 
hybrid (Ad/retrovirus) vector, transfected cells produce two 
types of functional progeny: a retroviral packaging functions 
and retroviral vector/transgene sequences. The progeny after 
release can infect neighboring cells leading to the incorpora-
tion of transgene.91
Nonviral vectors for CNS therapeutic gene delivery
Problems associated with viral vector gene delivery systems 
(eg, unwanted deleterious immune response or changes in 
the properties of delivered virus due to endogenous recom-
bination and mutagenic behavior leading to oncogenesis) 
lead to the development of nonviral vector delivery systems. 
This contains use of chemical carriers and naked gene 
delivery using electro-poration, gene gun (bio-ballistic or 
biolistic), ultrasound and hydrodynamics (high pressure).
Chemical carriers mediated 
CNS gene delivery
Chemical carriers are designed to protect the delivered DNA 
from nuclease activity. Nonviral vector such as cationic1 and 
anionic liposome3 with no immune response or toxicity have 
been reported. Although, the cationic liposome mediated 
gene transfer to different cell types is successful, this method 
is limited in use due to its lower transfection efﬁ  ciency in 
compared to viral systems. A novel compound, FuGene6,99 
has also been tested to transfer gene of choice using reporter 
plasmid pEF-beta galactosidase. This compound has less 
toxicity in comparison to the Lipofectamine, as shown by 
Trypane blue staining.
The novel compound FuGene6, a commercially-available 
cationic lipid, has a very high potential to transfer DNA into 
cells of glial origin, and might be an interesting candidate 
for ex vivo and in vivo gene therapeutic approaches.99 The 
FuGene6-mediated gene transfer is useful to transfer the 
reporter gene β-galactosidase into C6 glioma cells, primary 
glia, and primary neurons.100 The cationic liposome DNA 
complexes (CLDCs) produces signiﬁ  cant levels of expression 
of both reporter genes and biologically relevant genes in non-
parenchymal cells lining CNS.9 The intracerebroventricular 
or intrathecal injection of either CLDCs containing the 
β-galactosidase (β-Gal) gene produced patchy and widely 
scattered areas of β-Gal expression. The chloramphenicol 
acetyl transferase (CAT) reporter gene product is present at 
signiﬁ  cant levels after single intracerebroventricular injection. 
To improve efﬁ  ciency, the fusion proteins derived from the 
Sendai virus is incorporated into cationic liposomes to avoid 
degradation by endocytosis.101 Nonhistone chromatin pro-
teins, a high mobility group protein, have been incorporated 
into the liposome for the transfer of transgene at speciﬁ  c 
site.102 Many cationic polypeptides eg, polylysine, spermi-
dine, etc having capacity to bind the negatively charged DNA 
are used to target the gene transfer to the cell linked with 
speciﬁ  c ligands. Although liposome mediated gene transfer 
into the brain has nontoxic and nonimmunogenic effect, 
it has low efﬁ  ciency of transgene expression in compared 
to the viral mediated transgene expression. The ori-P and 
EBNA-1 gene elements from the EBV have been used in 
the liposome-associated DNA to prolong the stability of the Biologics: Targets & Therapy 2009:3 253
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transgene in the dividing cells.103 Biodegradable polymer, 
poly[α-(4-aminobutyl)-L-glycolic acid] (PAGA) a derivative 
of poly-L-lysine is under trial for delivery of transgene. Other 
than PAGA, PEG (polyethylene glycol) and peptide mediated 
(eg, Cys–Trp–Lys) are also under trial.
Physical forces-mediated CNS 
transgenes delivery
Successful transfer of naked DNA into the adult mouse 
brain has been reported. Microprocessor-controlled injector, 
an important tool for nonviral gene transfer technique, has 
successfully been used to deliver the gene into the CNS.40 
Reports are also available to show the use of electroporation 
technique to deliver naked transgene in the skin at particular 
site.104,105 Few reports show the success of in vivo electropora-
tion technique in the nervous system of embryonic mice106 that 
can be used to repair the injured or diseased CNS. In mice brain 
organotypic slice cultures, both biolistics and electroporation 
techniques provide better transfer rate and transgene expression 
than lipotransfection technique107 providing the use of nonviral 
techniques for therapeutic purposes in clinical studies.
Nanotechnology could also be used for the targeted gene 
delivery.108 Research is in progress to use this technology to 
transfer the gene or drug at particular site which is otherwise 
impossible in clinical studies. Studies are in progress to use ultra-
sound as a physical force to introduce transgenes in CNS.109
Conclusion
Genes with good expression ability of therapeutic molecules 
have signiﬁ  cant potential in CNS injury. Many viral vectors 
are available to deliver therapeutic genes at target site. How-
ever, CNS gene delivery remains a challenge. A smart viral 
delivery vehicle with optimal gene titer could solve the prob-
lems associated with CNS therapeutic gene delivery. In vivo 
studies suggest that recombinant virus along with lentivirus 
is a better and more promising vehicle for long-term efﬁ  cient 
transgene expression in CNS tissues. Other option perhaps is 
a nonviral, targeted transgenes delivery with CNS compatible 
biomaterial. This emerges as a viable option for CNS gene 
delivery and therapeutic expression for use in many neuronal 
diseases. In the place of in vivo gene delivery, ex vivo gene 
delivery techniques looks very exciting for the repair of lost 
tissues after TBI or necrosis in CNS.
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